Journal of Antimicrobial Chemotherapy (2000) 45, 583-590
© 2000 The British Society for Antimicrobial Chemotherapy
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones
Departments of Pathology and Medicine, Northwestern University Medical School, Divisions of Microbiology and Infectious Diseases, Northwestern Memorial Hospital, Chicago, IL 60611, USA
The in vitro activity of the novel 8-methoxyquinolone, moxifloxacin, against Streptococcus pneumoniae was evaluated, and the intracellular targets of this agent were studied. Analysis of mutant strains selected with moxifloxacin demonstrated that first-step mutants bore amino acid substitutions at position 81 in the GyrA subunit of DNA gyrase. This suggests that, unlike older fluoroquinolone agents such as ciprofloxacin and levofloxacin, but similar to other C-8 substituted quinolones like sparfloxacin and gatifloxacin, moxifloxacin targets the GyrA subunit of DNA gyrase as an initial lethal event. Such a mechanism results in high activity against increasingly common S. pneumoniae strains bearing substitutions in DNA topoisomerase IV. Moxifloxacin was active with an MIC of 
0.25 mg/L against S. pneumoniae clinical isolates, and against mutants, selected in the laboratory with ciprofloxacin or levofloxacin, that bore a Ser-79
Phe/Tyr substitution in ParC. The moxifloxacin MIC for strains with mutations in the structural genes for both DNA gyrase subunit GyrA and DNA topoisomerase IV subunit ParC did not exceed 2 mg/L, a level within clinically achievable serum concentrations for this agent. We also found that moxifloxacin is a poor substrate for active efflux in S. pneumoniae. Therefore, the high activity of moxifloxacin against S. pneumoniae appears to be a result of both enhanced activity against DNA gyrase and topoisomerase IV, and reduced efflux from the bacterial cell.
* Correspondence address. Microbiology Division, Department of Pathology, Wesley Pavilion, Room 565, Northwestern Memorial Hospital, 251 E. Huron, Chicago, IL 60611, USA. Tel: +1-312-926-2885; Fax: +1-312-926-4139; E-mail: lancer{at}nwu.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Grayo, M.-C. Lott-Desroches, O. Dussurget, R. Respaud, A. Fontanet, O. Join-Lambert, E. Singlas, and A. Le Monnier Rapid Eradication of Listeria monocytogenes by Moxifloxacin in a Murine Model of Central Nervous System Listeriosis Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3210 - 3215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Black, T. Stachyra, D. Platel, A.-M. Girard, M. Claudon, J.-M. Bruneau, and C. Miossec Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3339 - 3349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Okumura, T. Hirata, Y. Onodera, K. Hoshino, T. Otani, and T. Yamamoto Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., July 1, 2008; 62(1): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grayo, O. Join-Lambert, M. C. Desroches, and A. Le Monnier Comparison of the In Vitro Efficacies of Moxifloxacin and Amoxicillin against Listeria monocytogenes Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1697 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. DeRyke, X. Du, and D. P. Nicolau Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae J. Antimicrob. Chemother., September 1, 2006; 58(3): 601 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gao, M. E. Pennesi, X. Qiao, M. N. Iyer, S. M. Wu, E. R. Holz, and W. F. Mieler Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1606 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Khan, Z. M. Mirza, A. Kumar, V. Verma, and G. N. Qazi Piperine, a Phytochemical Potentiator of Ciprofloxacin against Staphylococcus aureus Antimicrob. Agents Chemother., February 1, 2006; 50(2): 810 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Strahilevitz and D. C. Hooper Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1949 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fuhrmann, P. Schenk, W. Jaeger, S. Ahmed, and F. Thalhammer Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration J. Antimicrob. Chemother., October 1, 2004; 54(4): 780 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 {blacktriangledown}Moxifloxacin - a new fluoroquinolone antibacterial DTB, August 1, 2004; 42(8): 61 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Eick, A. Schmitt, S. Sachse, K.-H. Schmidt, and W. Pfister In vitro antibacterial activity of fluoroquinolones against Porphyromonas gingivalis strains J. Antimicrob. Chemother., August 1, 2004; 54(2): 553 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Bast, A. Athamna, C. L. Duncan, J. C. S. de Azavedo, D. E. Low, G. Rahav, D. Farrell, and E. Rubinstein Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance J. Antimicrob. Chemother., July 1, 2004; 54(1): 90 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K Yoo, D. M Triller, C.-S. Yong, and T. P Lodise Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections Ann. Pharmacother., July 1, 2004; 38(7): 1226 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Florea, P. R. Tessier, C. Zhang, C. H. Nightingale, and D. P. Nicolau Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1215 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. R. Pletz, A. De Roux, A. Roth, K.-H. Neumann, H. Mauch, and H. Lode Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study Antimicrob. Agents Chemother., March 1, 2004; 48(3): 780 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Allen, G. W. Kaatz, and M. J. Rybak Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2606 - 2614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Fisher, K. A. Gould, X.-S. Pan, S. Patel, and V. J. Heaton Analysis of dual active fluoroquinolones in Streptococcus pneumoniae J. Antimicrob. Chemother., August 1, 2003; 52(2): 312 - 313. [Full Text] [PDF]
|
|
|
|
|
|
K. Drlica The mutant selection window and antimicrobial resistance J. Antimicrob. Chemother., July 1, 2003; 52(1): 11 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ince, X. Zhang, and D. C. Hooper Activity of and Resistance to Moxifloxacin in Staphylococcus aureus Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1410 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kishii, M. Takei, H. Fukuda, K. Hayashi, and M. Hosaka Contribution of the 8-Methoxy Group to the Activity of Gatifloxacin against Type II Topoisomerases of Streptococcus pneumoniae Antimicrob. Agents Chemother., January 1, 2003; 47(1): 77 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Boswell, J. M. Andrews, G. Jevons, and R. Wise Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance J. Antimicrob. Chemother., October 1, 2002; 50(4): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Houssaye, L. Gutmann, and E. Varon Topoisomerase Mutations Associated with In Vitro Selection of Resistance to Moxifloxacin in Streptococcus pneumoniae Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2712 - 2715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims J. Antimicrob. Chemother., June 1, 2002; 49(6): 893 - 895. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Jones, I. A. Critchley, J. A. Karlowsky, R. S. Blosser-Middleton, F.-J. Schmitz, C. Thornsberry, and D. F. Sahm In Vitro Activities of Novel Nonfluorinated Quinolones PGE 9262932 and PGE 9509924 against Clinical Isolates of Staphylococcus aureus and Streptococcus pneumoniae with Defined Mutations in DNA Gyrase and Topoisomerase IV Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1651 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. H. Manjunatha, M. Dalal, M. Chatterji, D. R. Radha, S. S. Visweswariah, and V. Nagaraja Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase Nucleic Acids Res., May 15, 2002; 30(10): 2144 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Brueggemann, S. L. Coffman, P. Rhomberg, H. Huynh, L. Almer, A. Nilius, R. Flamm, and G. V. Doern Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995 Antimicrob. Agents Chemother., March 1, 2002; 46(3): 680 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Pestova, J. J. Millichap, F. Siddiqui, G. A. Noskin, and L. R. Peterson Non-PmrA-mediated multidrug resistance in Streptococcus pneumoniae J. Antimicrob. Chemother., March 1, 2002; 49(3): 553 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Yague, J. E. Morris, X.-S. Pan, K. A. Gould, and L. M. Fisher Cleavable-Complex Formation by Wild-Type and Quinolone-Resistant Streptococcus pneumoniae Type II Topoisomerases Mediated by Gemifloxacin and Other Fluoroquinolones Antimicrob. Agents Chemother., February 1, 2002; 46(2): 413 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Li, X. Zhao, and K. Drlica Selection of Streptococcus pneumoniae Mutants Having Reduced Susceptibility to Moxifloxacin and Levofloxacin Antimicrob. Agents Chemother., February 1, 2002; 46(2): 522 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Morris, X.-S. Pan, and L. M. Fisher Grepafloxacin, a Dimethyl Derivative of Ciprofloxacin, Acts Preferentially through Gyrase in Streptococcus pneumoniae: Role of the C-5 Group in Target Specificity Antimicrob. Agents Chemother., February 1, 2002; 46(2): 582 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-S. Pan, G. Yague, and L. M. Fisher Quinolone Resistance Mutations in Streptococcus pneumoniae GyrA and ParC Proteins: Mechanistic Insights into Quinolone Action from Enzymatic Analysis, Intracellular Levels, and Phenotypes of Wild-Type and Mutant Proteins Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3140 - 3147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hartman-Neumann, K. DenBleyker, L. A. Pelosi, L. E. Lawrence, J. F. Barrett, and T. J. Dougherty Selection and Genetic Characterization of Streptococcus pneumoniae Mutants Resistant to the Des-F(6) Quinolone BMS-284756 Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2865 - 2870. [Abstract] [Full Text]
|
|
|
|
|
|
K. Nagai, T. A. Davies, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae J. Antimicrob. Chemother., September 1, 2001; 48(3): 365 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Bast, J. C. S. de Azavedo, T. Y. Tam, L. Kilburn, C. Duncan, L. A. Mandell, R. J. Davidson, and D. E. Low Interspecies Recombination Contributes Minimally to Fluoroquinolone Resistance in Streptococcus pneumoniae Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2631 - 2634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Millichap, E. Pestova, F. Siddiqui, G. A. Noskin, and L. R. Peterson Fluoroquinolone Resistance Is a Poor Surrogate Marker for Type II Topoisomerase Mutations in Clinical Isolates of Streptococcus pneumoniae J. Clin. Microbiol., July 1, 2001; 39(7): 2719 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Fukuda, R. Kishii, M. Takei, and M. Hosaka Contributions of the 8-Methoxy Group of Gatifloxacin to Resistance Selectivity, Target Preference, and Antibacterial Activity against Streptococcus pneumoniae Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1649 - 1653. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Richardson, D. Bast, A. McGeer, and D. E. Low Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1911 - 1914. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Blondeau, X. Zhao, G. Hansen, and K. Drlica Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae Antimicrob. Agents Chemother., February 1, 2001; 45(2): 433 - 438. [Abstract] [Full Text]
|
|